Results 71 to 80 of about 350,390 (302)
Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review
Respiratory Research, 2021 Background The COVID-19 pandemic has affected the world extraordinarily. This disease has a potential to cause a significantly severe course of disease leading to respiratory complications, multiple organ failure and possibly death.
Alina Kröker, Madara Tirzīte
doaj +1 more source
Prevention and treatment of ventilator-associated pneumonia in COVID-19
Frontiers in Pharmacology, 2022 Ventilator-associated pneumonia (VAP) is the most common acquired infection in the intensive care unit. Recent studies showed that the critical COVID-19 patients with invasive mechanical ventilation have a high risk of developing VAP, which result in a ...
Jiayi Deng +4 more
doaj +1 more source
Racing against COVID-19: a vaccines strategy for Europe. Bruegel Policy Contribution Issue n˚7 | April 2020 [PDF]
, 2020 The fast development of vaccines is an essential part of the long-term solution to COVID-19, but vaccine development has high costs and carries the risk of high failure rates.
Veugelers, Reinhilde, Zachmann, Georg.
core +1 more source
Syndromic and Point-of-Care Molecular Testing [PDF]
, 2018 This article is made available for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source.
Abbott, April N., Relich, Ryan F.
core +1 more source
Neoadjuvant endocrine therapy for luminal breast cancer treatment: a first-choice alternative in times of crisis such as the COVID-19 pandemic [PDF]
, 2020 The epidemiological emergency caused by CoV-2 (COVID-19) has changed priorities in breast cancer management. In those places where the pandemic has had the greatest effect, it is of paramount importance for most patients to be at home, reducing or ...
Martí, Covadonga +1 more
core +1 more source
Drug treatment for Covid-19 - three years later
Infectious Diseases Now, 2023 There has been a profusion of trials for SARS CoV2 drugs. A review dating from May 2020 listed 115 medicines, most of which previously existed, having been investigated since the onset of the pandemic. Over an exceedingly short lapse of time, the perspective of the arrival of a new antiviral treatment specifically targeting COVID-19 appeared highly ...
openaire +2 more sources
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Children with acute lymphoblastic leukemia (ALL) are at risk of severe outcomes from SARS‐CoV‐2 (SCV2). In the post‐pandemic context, where most children have been infected with SCV2, there are limited data on whether vaccination remains beneficial in children with ALL.
Janna R. Shapiro +11 more
wiley +1 more source
Repurposing the drug, ivermectin, in COVID-19: toxicological points of view
European Journal of Medical Research, 2022 The global COVID-19 pandemic has affected the world’s population by causing changes in behavior, such as social distancing, masking, restricting people’s movement, and evaluating existing medication as potential therapies.
Farshad M. Shirazi +5 more
doaj +1 more source
Frontiers in Pharmacology, 2022 COVID-19 is a highly contagious respiratory disease, which mainly affects the lungs. Critically ill patients are easily complicated by cytokine storms, acute respiratory distress syndrome (ARDS), and respiratory failure, which seriously threaten their ...
Hao Shen +14 more
doaj +1 more source
Digital Orthopaedics: A Glimpse Into the Future in the Midst of a Pandemic. [PDF]
, 2020 BackgroundThe response to COVID-19 catalyzed the adoption and integration of digital health tools into the health care delivery model for musculoskeletal patients. The change, suspension, or relaxation of Medicare and federal guidelines enabled the rapid
Ast, Michael P +9 more
core